fluxTrAM: Integration of tracer-based metabolomics data into atomically resolved genome-scale metabolic networks for metabolic flux analysis

Huang, L.; Preciat, G.; Alarcon-Gil, J.; Moreno, E. L.; Wegrzyn, A. B.; Thiele, I.; Schymanski, E. L.; Harms, A. C.; Fleming, R. M.; Hankemeier, T.

doi:10.1101/2024.11.26.625485

bioRxiv · 10.1101/2024.11.26.625485

fluxTrAM: Integration of tracer-based metabolomics data into atomically resolved genome-scale metabolic networks for metabolic flux analysis

Huang, L.·Preciat, G.·Alarcon-Gil, J.·Moreno, E. L.·Wegrzyn, A. B.·Thiele, I.·Schymanski, E. L.·Harms, A. C.·Fleming, R. M.·Hankemeier, T.

View original source ↗Export metadata ↓

Abstract

Quantitative inference of intracellular reaction rates is essential for characterising metabolic phenotypes. The classical experimental method for measuring metabolic fluxes makes use of stable-isotope tracing of metabolites through the metabolic network, followed by mass spectrometry analysis. The most common 13C-based metabolic flux analysis requires multidisciplinary knowledge in analytical chemistry, cell biology, and mathematical modelling, as well as the use of multiple independent tools for handling mass spectrometry data. Besides, flux analysis is usually carried out within a small network to validate a specific biological hypothesis. To overcome interdisciplinary barriers and extend flux interpretation towards a genome-scale level, we developed fluxTrAM, a semi-automated pipeline for processing tracer- based metabolomics data and integrating it with atomically resolved genome-scale metabolic networks to enable flux predictions at genome-scale. fluxTrAM integrates different software packages inside and outside of the COBRA Toolbox v3.4 for the generation of metabolite structure and reaction databases for a genome-scale model, labelled mass spectrometry data processing into standardised mass isotopologue distribution data (MID), and metabolic flux analysis. To demonstrate the utility of this pipeline, we generated 13C-labeled metabolomics data on an in vitro human induced pluripotent stem cell (iPSC)-derived dopaminergic neuronal culture and processed 13C-labeled MID datasets. In parallel, we generated a cheminformatic database of standardised and context-specific metabolite structures, and atom-mapped reactions for a genome-scale dopaminergic neuronal metabolic model. MID data could be exported into established flux inference software for conventional flux inference on a core model scale. It could also be integrated into the atomically resolved metabolic model for flux inference at genome-scale using moiety fluxomics method. The core model flux solution and moiety flux solution were then compared to two additional flux solutions predicted via flux balance analysis and entropic flux balance analysis. The extensive computational flux analysis and comparison helped to better evaluate the obtained flux feasibility of the neuron-specific genome-scale model and suggested new tracer-based metabolomics experiments with novel labeling configurations, such as labelling a moiety within the thymidine metabolite. Overall, fluxTrAM enables the automation of labelled liquid chromatography (LC)-mass spectrometry (MS) data processing into MID datasets and atom mapping for any given genome-scale metabolic model. It contributes to the standardisation and high throughput of metabolic flux analysis at genome- scale.

Explore related subjects

systems biology Preprint

Keep this discovery

Explore connections, maps & timelines

BibTeX RIS

Huang, L., Preciat, G., Alarcon-Gil, J., Moreno, E. L., Wegrzyn, A. B., Thiele, I., Schymanski, E. L., Harms, A. C., Fleming, R. M., Hankemeier, T.. 2024-12-02. fluxTrAM: Integration of tracer-based metabolomics data into atomically resolved genome-scale metabolic networks for metabolic flux analysis. https://doi.org/10.1101/2024.11.26.625485

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

bioRxiv2026

INFORME: coupling information-theoretic experimental design with nonlinear mixed-effects modeling for efficient observation scheduling

Mathematical models of treatment response can inform individualized therapy, but their calibration often requires longitudinal measurements that are costly, burdensome, and collected on fixed schedules. Such schedules may be inefficient, over-sampling patients whose response is already well characterized while delaying informative measurements for those whose model parameters remain uncertain. We present INFORME (INFORmation-theoretic design with Mixed Effects), a framework that combines Bayesian information-theoretic experimental design with nonlinear mixed-effects modeling to adaptively select each patients next measurement time. Population and response-subgroup parameter distributions learned from an existing cohort provide informative priors, allowing candidate measurement times to be ranked by their expected reduction in patient-specific parameter uncertainty. As observations accumulate, priors can be updated to reflect the response subgroup most consistent with the patients data. We evaluate INFORME in two radiotherapy datasets: 150 synthetic tumor volume trajectories from a hybrid cellular automaton model of prostate cancer spheroids (HD1) and longitudinal tumor volumes from 39 patients with head-and-neck cancer (HD2). In HD1, population priors allowed omission of both pretreatment scans, while adaptive scheduling reduced the protocol from nine scans to three or four, with the response group identified from a single post-treatment scan on day 27. In HD2, the adaptive schedule used three scans instead of six and improved prediction by delaying the first on-treatment scan from week 1 to week 2, avoiding transient dynamics that produced false-positive and false-negative response projections. Across both datasets, the adaptive schedules used a mean of 2.7 scans in stead of seven and advanced completion of the patient-specific prediction by a mean of 15.5 days (95% CI, 6.7-24.3) relative to the equidistant protocol, while treatment duration remained unchanged. INFORME therefore reduces measurement burden and accelerates patient-specific prediction by concentrating observations at times that are most informative for model calibration.

systems biology↗

bioRxiv2026

Sobetirome, a thyroid hormone receptor beta agonist, is a potential therapeutic agent for pulmonary fibrosis

Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal disease with limited treatment options. Our group previously identified the antifibrotic potential of thyroid hormone, triiodothyronine (T3); however, clinical translation of thyroid hormone therapy is limited by its systemic adverse effects. In this study, we investigate whether sobetirome, a selective and well tolerated thyroid hormone receptor beta (THRB) agonist, offers antifibrotic benefits of thyroid hormone while minimizing systemic toxicity. Our study reveals that sobetirome, administered via intraperitoneal or inhalational routes, effectively mitigates bleomycin-induced pulmonary fibrosis in mice, with no evidence of toxicity. We identified that sobetirome restores mitochondrial homeostasis via activating the THRB-PPARGC1a axis. This protects alveolar type II epithelial cells from injury-induced apoptosis while selectively inducing apoptosis and metabolic reprogramming in apoptosis resistant IPF fibroblasts. Cell-specific deletion of Ppargc1a in either alveolar epithelial cells or fibroblasts abolishes sobetirome-mediated protection, establishing PPARGC1a as an essential mediator of therapeutic response. Importantly, sobetirome reverses fibrosis-associated transcriptional programs in human IPF lung tissue, reducing expression of key fibrosis-associated genes, including collagen I alpha 1 (COL1A1), collagen III alpha 1 (COL3A1), periostin (POSTN), cathepsin K (CTSK), and Chitinase 3 Like 1 (CHI3L1), while promoting extracellular matrix remodeling, epithelial restoration, and tissue homeostasis. Collectively, our findings identify THRB activation as a novel metabolic strategy for reversing pulmonary fibrosis. Across complementary in vitro, in vivo, and human ex vivo models, sobetirome restores mitochondrial function, modulates apoptotic pathways in pathogenic cells, and promotes fibrosis resolution, highlighting its potential as a lung-targeted therapeutic approach for IPF and other fibrotic lung diseases.

systems biology↗

bioRxiv2026

Mechanistic modeling of bacterial translation initiation across growth conditions

Translation frequency in bacteria depends on how ribosomes, mRNAs, and initiation factors are allocated across growth conditions. Here, we developed a mechanistic ODE-based model of Escherichia coli translation that represents initiation, elongation, termination, and coupled auxiliary processes. Growth-dependent abundances were derived from physiological relationships and reprocessed omics data, and simulated outputs were compared with translation-frequency and active-ribosome references. The model predicts a continuous shift from complex-formation-limited toward ribosome-limited behavior as growth increases. This shift is characterized by a decline in free-ribosome abundance, whereas initiation-factor pools remain largely unbound and do not become depleted in parallel. Together with the implemented IF-dependent kinetic term, this preserved availability provides a model-internal route through which productive initiation can be maintained despite increasing ribosome utilization. Consistently, transcript-wide ribosome loading remains below its theoretical maximum, while COG-level simulations reveal distinct sector-specific translation-frequency trajectories. The study therefore provides a resource-allocation framework for interpreting how mRNA--ribosome interactions shape bacterial translation across growth conditions.

systems biology↗